BR0207705A - Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida - Google Patents

Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida

Info

Publication number
BR0207705A
BR0207705A BR0207705-1A BR0207705A BR0207705A BR 0207705 A BR0207705 A BR 0207705A BR 0207705 A BR0207705 A BR 0207705A BR 0207705 A BR0207705 A BR 0207705A
Authority
BR
Brazil
Prior art keywords
cntf
neurotrophic factor
reduced
ciliary neurotrophic
imonogenicity
Prior art date
Application number
BR0207705-1A
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Original Assignee
Merc Patent Ges Mit Beschraenk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merc Patent Ges Mit Beschraenk filed Critical Merc Patent Ges Mit Beschraenk
Publication of BR0207705A publication Critical patent/BR0207705A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"FATOR NEUROTRóFICO CILIAR MODIFICADO (CNTF) COM IMUNOGENICIDADE REDUZIDA". A presente invenção refere-se a polipeptídeos a serem administrados especialmente a humanos e, particularmente, para uso terapêutico. Os polipeptídeos são polipeptídeos modificados em que a modificação resulta em uma propensão reduzida para o polipeptídeo elicitar uma resposta imune quando da administração ao indivíduo humano. A invenção refere-se, particularmente, à modificação de fator neurotrófico ciliar humano (CNTF) para resultar em proteínas de CNTF que são substancialmente não-imunogênicas ou menos imunogênicas do que qualquer contraparte não-modificada quando usadas in vivo.
BR0207705-1A 2001-03-02 2002-02-27 Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida BR0207705A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105089 2001-03-02
PCT/EP2002/002084 WO2002070698A2 (en) 2001-03-02 2002-02-27 Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity

Publications (1)

Publication Number Publication Date
BR0207705A true BR0207705A (pt) 2004-03-23

Family

ID=8176647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207705-1A BR0207705A (pt) 2001-03-02 2002-02-27 Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida

Country Status (13)

Country Link
US (1) US20040087503A1 (pt)
EP (1) EP1379655A2 (pt)
JP (1) JP2004529629A (pt)
KR (1) KR20030081480A (pt)
CN (1) CN1494593A (pt)
BR (1) BR0207705A (pt)
CA (1) CA2439682A1 (pt)
HU (1) HUP0303310A2 (pt)
MX (1) MXPA03007839A (pt)
PL (1) PL362704A1 (pt)
RU (1) RU2003129069A (pt)
WO (1) WO2002070698A2 (pt)
ZA (1) ZA200307678B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014641A2 (en) * 2003-07-09 2005-02-17 Xencor, Inc. Ciliary neurotrophic factor variants
WO2005033137A1 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
DE102011104822A1 (de) 2011-06-18 2012-12-20 Christian-Albrechts-Universität Zu Kiel Ciliary-Neutrophic-Factor-Varianten
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
EP3218833A2 (en) * 2014-11-14 2017-09-20 D.E. Shaw Research, LLC Suppressing interaction between bonded particles
US11208462B2 (en) * 2016-12-06 2021-12-28 The Board Of Trustees Of The Leland Stanford Junior University Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
CA2123234A1 (en) * 1991-11-11 1993-05-27 Lanfranco Callegaro Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
AU1282895A (en) * 1993-12-29 1995-07-17 Sumitomo Pharmaceuticals Company, Limited Novel human ciliary neurotrophic factor
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
JP2003507393A (ja) * 1999-08-13 2003-02-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法

Also Published As

Publication number Publication date
RU2003129069A (ru) 2005-04-20
CN1494593A (zh) 2004-05-05
EP1379655A2 (en) 2004-01-14
JP2004529629A (ja) 2004-09-30
ZA200307678B (en) 2004-08-31
WO2002070698A3 (en) 2003-11-20
WO2002070698A2 (en) 2002-09-12
CA2439682A1 (en) 2002-09-12
US20040087503A1 (en) 2004-05-06
HUP0303310A2 (hu) 2003-12-29
KR20030081480A (ko) 2003-10-17
MXPA03007839A (es) 2003-12-08
PL362704A1 (en) 2004-11-02

Similar Documents

Publication Publication Date Title
BR0207016A (pt) Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
BR0207018A (pt) Leptina modificada com imunogenicidade reduzida
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BR0007840A (pt) Proteìnas de fusão her-2/neu
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BR0207705A (pt) Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
BR9907228A (pt) Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória
FI893783A (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida
BR0207945A (pt) Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade
BR0207014A (pt) Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida.
BR0308860A (pt) Fator viii modificado
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
BR0207017A (pt) Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida
BR0207542A (pt) Trombopoietina modificada com imunogenicidade reduzida
NO20042055L (no) Tymosinalfa 1-peptid/polymerkonjugater
BR0207020A (pt) Fator de estimulação de colÈnia por granulócito (g-csf) modificado com imunogenicidade reduzida
BR0208120A (pt) Insulina modificada com imunogenicidade reduzida
WO2003006047A3 (en) Methods for reducing immunogenicity of polypeptides
BR0211991A (pt) HormÈnio do crescimento humano modificado
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.